Research ArticleOriginal Article
Open Access

CYP2D6 genetic polymorphisms in Saudi systemic lupus erythematosus patients

A cross-sectional study

Lena M. Hassen, Maha H. Daghestani, Mohammed A. Omair, Arwa K. Althomali, Fatimah B. Almukaynizi and Ibrahim A. Almaghlouth
Saudi Medical Journal March 2023, 44 (3) 237-245; DOI: https://doi.org/10.15537/smj.2023.44.3.20220581

References

  1. 1.↵
    1. Yu A,
    2. Kneller BM,
    3. Rettie AE,
    4. Haining RL. Expression
    , purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 2002; 303: 1291–1300.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Gaedigk A,
    2. Sangkuhl K,
    3. Whirl-Carrillo M,
    4. Klein T,
    5. Leeder JS.
    Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 2017; 19: 69–76.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Koopmans AB,
    2. Braakman MH,
    3. Vinkers DJ,
    4. Hoek HW,
    5. van Harten PN.
    Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry 2021; 11: 141.
    OpenUrl
  4. 4.↵
    1. McKinnon RA,
    2. Nebert DW.
    Possible role of cytochromes P450 in lupus erythematosus and related disorders. Lupus 1994; 3: 473–478.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Lee YH,
    2. Bae SC.
    Association between functional CYP2D6 polymorphisms and susceptibility to autoimmune diseases: a meta-analysis. Immunol Invest 2017; 46: 109–122.
    OpenUrlCrossRef
  6. 6.↵
    1. Kortunay S,
    2. Bozkurt A,
    3. Bathum L,
    4. Basci NE,
    5. Calgüneri M,
    6. Brøsen K, et al.
    CYP2D6 polymorphism in systemic lupus erythematosus patients. Eur J Clin Pharmacol 1999; 55: 21–25.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Skrętkowicz J,
    2. Barańska M,
    3. Kaczorowska A,
    4. Rychlik-Sych M.
    Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus. Arch Med Sci 2011; 7: 864–869.
    OpenUrlPubMed
  8. 8.↵
    1. Barańska M,
    2. Rychlik-Sych M,
    3. Kaszuba A,
    4. Dziankowska-Bartkowiak B,
    5. Skrętkowicz J,
    6. Waszczykowska E.
    Genetic polymorphism of CYP2D6 in patients with systemic lupus erythematosus and systemic sclerosis. Autoimmunity 2016: 1–6.
  9. 9.↵
    1. Petri M,
    2. Orbai AM,
    3. Alarcón GS,
    4. Gordon C,
    5. Merrill JT,
    6. Fortin PR, et al.
    Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Al-Dosari MS,
    2. Al-Jenoobi FI,
    3. Alkharfy KM,
    4. Alghamdi AM,
    5. Bagulb KM,
    6. Parvez MK, et al.
    High prevalence of CYP2D6*41 (G2988A) allele in Saudi Arabians. Environ Toxicol Pharmacol 2013; 36: 1063–1067.
    OpenUrl
  11. 11.↵
    1. Al-Arfaj AS,
    2. Al-Balla SR,
    3. Al-Dalaan AN,
    4. Al-Saleh SS,
    5. Bahabri SA,
    6. Mousa MM, et al.
    Prevalence of systemic lupus erythematosus in central Saudi Arabia. Saudi Med J 2002; 23: 87–89.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Almaghlouth IA,
    2. Hassen LM,
    3. Alahmari HS,
    4. Bedaiwi A,
    5. Albarrak R,
    6. Daghestani M, et al.
    National systemic lupus erythematosus prospective cohort in Saudi Arabia: a study protocol. Medicine (Baltimore) 2021; 100: e26704.
    OpenUrl
  13. 13.↵
    1. Elfaki I,
    2. Mir R,
    3. Almutairi FM,
    4. Duhier FMA.
    Cytochrome P450: polymorphisms and roles in cancer, diabetes, and atherosclerosis. Asian Pac J Cancer Prev 2018; 19: 2057–2070.
    OpenUrl
  14. 14.↵
    1. Al Dhanhani AM,
    2. Agarwal M,
    3. Othman YS,
    4. Bakoush O.
    Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE. Lupus 2017; 26: 664–669.
    OpenUrl
  15. 15.↵
    1. Kouhi H,
    2. Hamzeiy H,
    3. Barar J,
    4. Asadi M,
    5. Omidi Y.
    Frequency of 5 important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan). Genet Test Mol Biomarkers 2009; 13: 665–670.
    OpenUrlPubMed
  16. 16.↵
    1. Aynacioglu AS,
    2. Sachse C,
    3. Bozkurt A,
    4. Kortunay S,
    5. Nacak M,
    6. Schröder T, et al.
    Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999; 66: 185–192.
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Fuselli S,
    2. Dupanloup I,
    3. Frigato E,
    4. Cruciani F,
    5. Scozzari R,
    6. Moral P, et al.
    Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet 2004; 12: 916–924.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Luo HR,
    2. Aloumanis V,
    3. Lin KM,
    4. Gurwitz D,
    5. Wan YJ.
    Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics 2004; 4: 395–401.
    OpenUrlPubMed
  19. 19.↵
    1. Mohammed Alkreathy H,
    2. Mohammed Eid Alsayyid K,
    3. Alaama JY,
    4. Al Ghalayini K,
    5. Karim S,
    6. Esmat A, et al.
    Bisoprolol responses (PK/PD) in hypertensive patients: a cytochrome P450 (CYP) 2D6 targeted polymorphism study. Saudi J Biol Sci 2020; 27: 2727–2732.
    OpenUrl
  20. 20.↵
    1. Qumsieh RY,
    2. Ali BR,
    3. Abdulrazzaq YM,
    4. Osman O,
    5. Akawi NA,
    6. Bastaki SM.
    Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis. PLoS One 2011; 6: e28943.
    OpenUrlPubMed
  21. 21.↵
    1. Aklillu E,
    2. Herrlin K,
    3. Gustafsson LL,
    4. Bertilsson L,
    5. Ingelman-Sundberg M.
    Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 2002; 12: 375–383.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Millo D,
    2. Bonifacio A,
    3. Moncelli MR,
    4. Sergo V,
    5. Gooijer C,
    6. van der Zwan G.
    Characterization of hybrid bilayer membranes on silver electrodes as biocompatible SERS substrates to study membrane-protein interactions. Colloids Surf B Biointerfaces 2010; 81: 212–216.
    OpenUrlPubMed
  23. 23.↵
    1. Sun J,
    2. Sui X,
    3. Bradbury JA,
    4. Zeldin DC,
    5. Conte MS,
    6. Liao JK.
    Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 2002; 90: 1020–1027.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Askari A,
    2. Thomson SJ,
    3. Edin ML,
    4. Zeldin DC,
    5. Bishop-Bailey D.
    Roles of the epoxygenase CYP2J2 in the endothelium. Prostaglandins Other Lipid Mediat 2013; 107: 56–63.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Alghasham A,
    2. Ali A,
    3. Ismail H,
    4. Dowaidar M,
    5. Settin AA.
    CYP2J2 -50 G/T and ADRB2 G46A gene polymorphisms in Saudi subjects with hypertension. Genet Test Mol Biomarkers 2012; 16: 1027–1031.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Leung N,
    2. Eirin A,
    3. Irazabal MV,
    4. Maddox DE,
    5. Gunderson HD,
    6. Fervenza FC, et al.
    Acute kidney injury in patients with inactive cytochrome P450 polymorphisms. Ren Fail 2009; 31: 749–752.
    OpenUrlPubMed
  27. 27.↵
    1. Trenaman SC,
    2. Bowles SK,
    3. Andrew MK,
    4. Goralski K.
    The role of gender, age, and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. Pharmacol Res Perspect 2021; 9: e00775.
    OpenUrl
  28. 28.↵
    1. Murray GI,
    2. McFadyen MC,
    3. Mitchell RT,
    4. Cheung YL,
    5. Kerr AC,
    6. Melvin WT.
    Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 1999; 79: 1836–1842.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Mitsui Y,
    2. Chang I,
    3. Fukuhara S,
    4. Hiraki M,
    5. Arichi N,
    6. Yasumoto H, et al.
    CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma. BMC Cancer 2015; 15: 942.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Barliana MI,
    2. Afifah NN,
    3. Amalia R,
    4. Hamijoyo L,
    5. Abdulah R.
    Genetic polymorphisms and the clinical response to systemic lupus erythematosus treatment towards personalized medicine. Front Pharmacol 2022; 13: 820927.
    OpenUrl
  31. 31.↵
    1. Khalaj Z,
    2. Baratieh Z,
    3. Nikpour P,
    4. Khanahmad H,
    5. Mokarian F,
    6. Salehi R, et al.
    Distribution of CYP2D6 polymorphism in the Middle Eastern region. J Res Med Sci 2019; 24: 61.
    OpenUrl
  32. 32.↵
    1. Zalata A,
    2. El-Samanoudy AZ,
    3. Osman G,
    4. Elhanbly S,
    5. Nada HA,
    6. Mostafa T.
    Cytochrome P450-2D6*4 polymorphism seminal relationship in infertile men. Andrologia 2015; 47: 525–530.
    OpenUrl
  33. 33.
    1. Eyada TK,
    2. El Ghonemy EG,
    3. El Ghoroury EA,
    4. El Bassyouni SO,
    5. El Masry MK.
    Study of genetic polymorphism of xenobiotic enzymes in acute leukemia. Blood Coagul Fibrinolysis 2007; 18: 489–495.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Zayed AA,
    2. Ahmed AI,
    3. Khattab AM,
    4. Mekdad AA
    , AbdelAal AG. Paraoxonase 1 and cytochrome P450 polymorphisms in susceptibility to acute organophosphorus poisoning in Egyptians. Neurotoxicology 2015; 51: 20–26.
    OpenUrl
  35. 35.↵
    1. Zanger UM,
    2. Momoi K,
    3. Hofmann U,
    4. Schwab M,
    5. Klein K.
    Tri-allelic haplotypes determine and differentiate functionally normal allele CYP2D6*2 and impaired allele CYP2D6*41. Clin Pharmacol Ther 2021; 109: 1256–1264.
    OpenUrl
  36. 36.↵
    1. Haduch A,
    2. Daniel WA.
    The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders. Drug Metab Rev 2018; 50: 415–429.
    OpenUrl
  37. 37.↵
    1. Sheng Y,
    2. Yang H,
    3. Wu T,
    4. Zhu L,
    5. Liu L,
    6. Liu X.
    Alterations of cytochrome P450s and UDP-glucuronosyltransferases in brain under diseases and their clinical significances. Front Pharmacol 2021; 12: 650027.
    OpenUrl
  38. 38.↵
    1. Hu X,
    2. Zhang M,
    3. Bai H,
    4. Wu L,
    5. Chen Y,
    6. Ding L, et al.
    Antituberculosis drug-induced adverse events in the liver, kidneys, and blood: clinical profiles and pharmacogenetic predictors. Clin Pharmacol Ther 2018; 104: 326–334.
    OpenUrl
  39. 39.↵
    1. Lee JY,
    2. Vinayagamoorthy N,
    3. Han K,
    4. Kwok SK,
    5. Ju JH,
    6. Park KS, et al.
    Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 2016; 68: 184–190.
    OpenUrl
  40. 40.↵
    1. Lee ST,
    2. Ryu S,
    3. Kim SR,
    4. Kim MJ,
    5. Kim S,
    6. Kim JW, et al.
    Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol 2012; 32: 441–448.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords